MyControl Support - A brand new support program for patients with obesity
Today, Navamedic launches MyControl Support in Sweden – a completely new support program aimed for people with obesity.
This is a first of its kind in obesity treatment in the Nordic markets with the ambition to offer patients additional support throughout a 6-month treatment period to increase adherence to their treatment. Roll out in other Nordic countries will follow.
The support program is following the launch of the previously announced information platform; MyControl and is part of Navamedic’s strategy to provide both information and secure treatments for patients with obesity.
“Launching a platform like this is by far one of the most ambitious and innovative initiatives we have offered the health care system. This is continuing our efforts in attempting to highlight the complexity surrounding this disease and offering both health care professionals and patients a treatment option complementing and strengthening a regular treatment protocol.” says Kathrine Gamborg Andreassen, CEO of Navamedic.
MyControl Support contains elements such as information about behavioural change, social and environmental challenges, nutritional planning as well as a tool for building and maintaining healthy habits. Patients on a specific medicinal treatment will also receive individual phone support with a licensed nurse throughout the program (this may vary between countries).
For further information, please contact:
Kathrine Gamborg Andreassen, CEO
Navamedic ASA is a Nordic pharma company and a reliable supplier of high-quality products, delivered to hospitals and through pharmacies, meeting the specific medical needs of patients and consumers. Navamedic is present in all Nordic countries, the Baltics and Benelux and has sales of specific products even in other European countries like UK and Greece. Our headquarter is in Oslo, Norway and we are listed on the Oslo Stock Exchange (ticker: NAVA).
For more information, please visit www.navamedic.com